ViaCord® to Advance Cord Blood Stem Cell Therapy Research through Collaboration with the Center for International Blood and

  ViaCord® to Advance Cord Blood Stem Cell Therapy Research through
  Collaboration with the Center for International Blood and Marrow Transplant
  Research®

 PerkinElmer’s family cord blood banking business and international research
 organization collaborates to analyze quality and outcomes of cord blood stem
                                  cell units

Business Wire

WALTHAM, Mass. -- April 30, 2013

ViaCord, PerkinElmer’s family cord blood and tissue preservation business, is
collaborating with the Center for International Blood and Marrow Transplant
Research (CIBMTR) to collect, maintain and publish research from ViaCord’s
cord blood stem cell transplants. This collaboration will expand knowledge of
cord blood-derived stem cell applications throughout the medical and research
community. To date, CIBMTR’s large network of transplant centers has resulted
in the development of a clinical database of more than 30,000 cord blood
transplant recipients for clinical decision-making, use in studies, and other
research purposes with the goal of making a profound impact on the survival of
cord blood transplant patients around the world. CIBMTR will work directly
with ViaCord to collect and analyze data to better understand the quality and
any outcome metrics of ViaCord’s released cord blood stem cell units as well
as how the units are being used.

“Collaborating with CIBMTR, which has established the industry standard for
collecting data around hematopoietic cellular therapy and regenerative
medicine, allows us to simultaneously gain insights into the effectiveness of
the cord blood stem cell units we have released for use as well as outcomes
from their clinical application,” said Morey Kraus, Chief Scientific Officer,
ViaCord. “We are then able to incorporate data from our transplanted units
into the larger database, which may be accessed for other CIBMTR studies by
the medical and scientific community to further their research and
understanding of cord blood stem cells.”

ViaCord is working with CIBMTR to collect and publish data as well as identify
outcomes unique to related or autologous (stem cells from the same patient)
transplants. The collaboration will also enable the analysis of umbilical cord
units released for potential future use in autologous cell therapy and
regenerative medicine clinical trials, including Cerebral Palsy, Type 1
Diabetes and others.

“The science of cord blood and cord tissue stem cells is growing at a rapid
pace,” said  J. Douglas Rizzo, M.D., M.S., Associate Scientific Director,
CIBMTR. “We are excited to collaborate with ViaCord to provide data and
analytic expertise that will assist the development of the field through
research.”

ViaCord's family cord blood banking services currently offers expectant
families the opportunity to preserve their baby's umbilical cord blood for
potential medical use by the child or a related family member. Families are
also preserving their baby’s umbilical cord tissue because research suggests
that one day these special cells may have the potential to treat medical
conditions that are untreatable today. ViaCord has preserved the umbilical
cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem
cells were used to treat just one disease, Fanconi's anemia. Today, cord blood
stem cells have been used in the treatment of nearly 80 diseases, including
cancers, certain blood disorders and immunodeficiencies. Please visit
www.viacord.com for more information.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements relating to estimates and projections of future
earnings per share, cash flow and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans concerning
business development opportunities and divestitures. Words such as "believes,"
"intends," "anticipates," "plans," "expects," "projects," "forecasts," "will"
and similar expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of important
risk factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products declining or not growing as anticipated; (2) fluctuations in the
global economic and political environments; (3) our failure to introduce new
products in a timely manner; (4) our ability to execute acquisitions and
license technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them profitable,
or successfully divest businesses; (5) our failure to adequately protect our
intellectual property; (6) the loss of any of our licenses or licensed rights;
(7) our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package delivery
and import/export services or significant increases in prices for those
services; (10) disruptions in the supply of raw materials and supplies; (11)
the manufacture and sale of products exposing us to product liability claims;
(12) our failure to maintain compliance with applicable government
regulations; (13) regulatory changes; (14) our failure to comply with
healthcare industry regulations; (15) economic, political and other risks
associated with foreign operations; (16) our ability to retain key personnel;
(17) significant disruption in our information technology systems; (18) our
ability to obtain future financing; (19) restrictions in our credit
agreements; (20) our ability to realize the full value of our intangible
assets; (21) significant fluctuations in our stock price; (22) reduction or
elimination of dividends on our common stock; and (23) other factors which we
describe under the caption "Risk Factors" in our most recent quarterly report
on Form 10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the
date of this press release.

About the Center for International Blood and Marrow Transplant Research^®
(CIBMTR)
A combined research program of the National Marrow Donor Program^® and the
Medical College of Wisconsin, the CIBMTR facilitates critical, cutting-edge
research that has led to increased survival and an enriched quality of life
for thousands of patients. The CIBMTR collaborates with the global scientific
community to advance hematopoietic cell transplantation and cellular therapy
research worldwide. The prospective and observational research is accomplished
through scientific and statistical expertise, a large network of transplant
centers and clinical database of more than 350,000 transplant recipients.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.

Contact:

Edelman (On behalf of PerkinElmer, Inc.)
Jen Reid, 404-460-8587
jen.reid@edelman.com